2seventy bio, Inc.

NasdaqGS:TSVT Stock Report

Market Cap: US$162.0m

2seventy bio Past Earnings Performance

Past criteria checks 0/6

2seventy bio has been growing earnings at an average annual rate of 12.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 6.2% per year.

Key information

12.3%

Earnings growth rate

31.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-6.2%
Return on equity-41.5%
Net Margin-207.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

2seventy bio: All In On Abecma Multiple Myeloma Treatment

Dec 23

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

Nov 15
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04
2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11
Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07
These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06
2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17
Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13
2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05
Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21
Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19
2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

Oct 04
We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

Sep 08

2seventy bio Prospects

Aug 23

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12
Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Revenue & Expenses Breakdown

How 2seventy bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:TSVT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2446-95520
30 Jun 2444-156520
31 Mar 2471-223610
31 Dec 23100-218690
30 Sep 23146-184720
30 Jun 23147-180790
31 Mar 23125-215760
31 Dec 2291-254790
30 Sep 2251-292850
30 Jun 2257-284890
31 Mar 2251-291930
31 Dec 2155-292940
30 Sep 2148-308910
30 Jun 2148-320900
31 Mar 21150-222920
31 Dec 20248-120910
31 Dec 1944-321820
31 Dec 1855-200540

Quality Earnings: TSVT is currently unprofitable.

Growing Profit Margin: TSVT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TSVT is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare TSVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TSVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: TSVT has a negative Return on Equity (-41.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:55
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

2seventy bio, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Samantha Lynn SemenkowCitigroup Inc
Samantha Lynn SemenkowCitigroup Inc